论文部分内容阅读
非小细胞肺癌的发病率和病死率近年呈上升趋势,化学治疗(化疗)是治疗非小细胞肺癌的主要手段;但是由于耐药的存在,化疗疗效有效率有限,目前一线化疗联合方案的有效率仅为20%~40%。近年来随着肿瘤分子生物学的发展,已发现ERCC1等基因的表达水平和化疗药物疗效及预后密切相关,ERCC1的表达水平有可能成为预测疗效进行个体化治疗的重要指标。根据基因表达水平及药物敏感情况选择个体化的化疗方案是肿瘤学研究和临床肿瘤化疗的趋势。
The incidence and mortality of non-small cell lung cancer have been on the rise in recent years. Chemotherapy (chemotherapy) is the main treatment for non-small cell lung cancer. However, due to the existence of drug resistance, the curative effect of chemotherapy is limited. Efficiency is only 20% ~ 40%. In recent years, along with the development of tumor molecular biology, it has been found that the expression level of ERCC1 and other genes are closely related to the curative effect and prognosis of chemotherapeutic drugs. The expression level of ERCC1 may become an important index for individualized treatment of predicting the curative effect. According to the level of gene expression and drug sensitivity to select individualized chemotherapy regimen is the trend of oncology research and clinical cancer chemotherapy.